Status
Conditions
About
calculate cardiovascular risk scores in type 2 DM patients, then estimate its association with new visceral adipose tissue indices
Full description
Cardiovascular disease (CVD) constitutes a significant health challenge for individuals with type 2 diabetes mellitus (T2DM), affecting approximately 32% of this population and contributing significantly to global mortality.Visceral adipose tissue (VAT) accumulation has been recognized as a major contributor to adverse cardiac remodelling. Unlike subcutaneous adipose tissue (SAT), VAT is metabolically active, promoting a pro-inflammatory, lipotoxic, and insulin-resistant environment that accelerates myocardial fibrosis, hypertrophy, and diastolic dysfunction. Despite its clinical significance, VAT is challenging to measure in routine practice. Advanced imaging modalities such as magnetic resonance imaging provide direct VAT assessment but it's costly, time-consuming, and impractical for large-scale screening. In contrast, traditional anthropometric measures like body mass index (BMI), waist circumference (WC), and waist-to-hip ratio (WHR) do not distinguish VAT from SAT and fail to capture the true cardiometabolic burden of visceral fat .To address these limitations, researchers have focused on developing non-invasive visceral obesity indices that combine anthropometric and laboratory-based parameters. These indices are particularly relevant for T2DM patients, as insulin resistance often occurs when fat accumulates in intra-abdominal depots and is associated with a constellation of CVD risk factors, in what is known as the metabolic syndrome.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Patient with a history of cardiovascular events
Patient with type 1 diabetes or gestational diabetes.
Pregnant women.
Hypothyroidism,
Cushing disease
polycystic ovarian syndrome.
Congestive heart failure
chronic liver disease
.- chronic kidney disease,
cancer
Current use of steroids, birth control pills, antipsychotics, antidepressants, epilepsy drugs.
Patients with physical deformities or conditions affecting anthropometric measurements.
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal